Skip to main content

Table 1 Baseline clinical and pathological characteristics

From: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Characteristics Enrolled patients
(n = 49)
Age (years)
Median 67 (61–75)
Gender  
Male 29 (59%)
Female 20 (41%)
ECOG
0–1 38 (78%)
2 11 (22%)
Ann Arbor stage
II 9 (18%)
III 15 (31%)
IV 25 (51%)
LDH
Normal 8 (16%)
Elevated 41 (84%)
Extranodal sites
0–1 20 (41%)
 ≥ 2 29 (59%)
IPI
2 7 (14%)
3 17 (35%)
4 20 (41%)
5 5 (10%)
Cell of origin
GCB 14 (29%)
non-GCB 35 (71%)
Double expressor lymphoma
Yes 12 (25%)
No 37 (75%)
  1. ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, IPI International Prognostic Index